Navigation Links
One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org
Date:12/30/2008

Today, iGuard.org, a free and secure medication monitoring service, registered its one-millionth member just 14 months after its launch last year. iGuard.org’s rapid growth highlights the growing trend toward patients taking a more active role in managing their own healthcare.

PRINCETON, N.J. (Business Wire EON) December 30, 2008 -- Helping Patients and Physicians

"Despite enormous investment of time and money in healthcare information technology, patients don't feel confident that the healthcare system is watching out for them," said Hugo Stephenson, MD, iGuard.org's founder. "iGuard.org is a really simple service. With most Americans getting their prescriptions from many different doctors, iGuard.org enables patients to register their medications for monitoring and sends them customized email drug safety reports, safety alerts and recalls from a pharmacist as new and personally relevant information emerges."

Barbara Munroe of Phoenix, Ariz. is an iGuard.org member who has epilepsy and takes numerous medications. "After wasting away for a year with no energy, I registered all my medicines on iGuard.org," said Munroe. "To my surprise, I soon received an alert about an interaction between Paxil and another medication I'm taking, Zonegran. Since deleting Paxil from my medications my energy has soared. Without iGuard.org's information, I would still be on the couch -- or worse. It has saved my life."

The iGuard.org Service

iGuard.org maintains an up-to-date database of drug-drug and drug-disease interactions, including feeds from the U.S. Food and Drug Administration (FDA) and major drug manufacturers, to provide users with personalized drug safety reports, safety alerts and product recalls by email. Since iGuard.org pharmacists write and review all alerts for a consumer audience, patients receive understandable, actionable, timely information that they can discuss with their doctors.

Paul Seligman, M.D., M.P.H., Associate Director for Safety Policy and Communication at the FDA, said, "Communicating safety information in a timely fashion is important to all those whoweigh the benefits and risks aboutthe appropriate use of a medicine. Providing this information is a shared responsibility of many in the healthcare system. iGuard.org now provides such a source for this information."

iGuard.org is Different from Other Drug Information Services

Although patients today have access to an enormous set of tools for getting information about their health, iGuard.org is the only service that:

helps patients identify which drugs pose the greatest risk using a personalized, color-coded, drug safety rating system; detects potential interactions between drugs and diseases as well as interactions between drugs – recognizing that drug-disease interactions (e.g., Viagra and heart disease, birth control pills and smoking) are the highest cause of death and disability associated with medication use; communicates emerging product recalls (which outnumber alerts by four to one) as well as safety notifications and FDA advisories; avoids bombarding patients with irrelevant communications by ensuring that drug-specific messages are sent only to those users to whom they apply; ensures that communications are actionable and easy to understand by having a pharmacist review and update FDA / drug company alerts for the consumer audience; allows patients to have their doctor copied on their communications; is funded by medical research, not by advertising, which helps improve medicines. Helping the Scientific Community

iGuard.org connects patients with researchers interested in learning more about how drugs work. iGuard has already helped researchers to document real world rates of side effects for common medications such as statins and antidepressants, and to discover potential interactions between prescription and over-the-counter medications. "Connecting real patients in the real world with drug researchers allows us to learn about medicines much faster," Dr. Stephenson said.

About iGuard.org

iGuard.org, headquartered in Princeton, N.J., is a free and secure source of information for registered users who want to get informed, stay informed and share feedback about their medications. It has received critical support from patient advocacy groups concerned by the large number of patients affected by serious, preventable adverse drug interactions. It offers balanced and timely information to help patients manage their healthcare for themselves or loved ones.

Registration is free online at iGuard.org, or through its partners including the Institute for Safe Medication Practices (www.consumermedsafety.org), participating e-prescribing physicians (www.allscripts.com) and select pharmacies.

Read the full story at http://www.prweb.com/releases/drug_safety/safety_alerts/prweb1807844.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org 
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: